Pinealon · Research brief

Pinealon Concentration for Research — Standard Protocols

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

51 WORDS

Short answer

Key takeaways

Pinealon research concentration ranges 0.5–5mg/mL depending on administration route, with 1–2mg/mL being standard for subcutaneous protocols in rodent models.
The concentration you prepare must keep injection volumes below 200μL for mice and 500μL for rats to avoid tissue trauma and variable absorption.
Reconstituted pinealon stored at 2–8°C remains stable for 28 days when using bacteriostatic water; higher concentrations (above 3mg/mL) show accelerated degradation and should be used within 21 days.
Temperature excursions above 8°C cause irreversible peptide bond hydrolysis. A single overnight storage failure can reduce biological activity by 20–40%.
Published protocols from Russian research institutions frequently use 1mg/kg subcutaneous doses reconstituted to 1mg/mL, translating to approximately 100μL injection volumes per 100g body weight.
Lower concentrations (below 0.5mg/mL) require impractically large injection volumes and degrade faster due to increased surface area exposure.

The standard concentration for pinealon in preclinical research isn't arbitrary. It's calibrated to match bioavailability windows observed in human pharmacokinetic studies. Most protocols use 0.5–5mg/mL depending on administration route, but the choice determines both receptor saturation and waste minimisation. Our team has worked with researchers across multiple institutions optimising peptide protocols. The gap between effective concentration and protocol failure comes down to three variables most guides never mention: storage temperature post-reconstitution, injection volume constraints, and the stability window of diluted peptide solutions.

How concentrated should pinealon be for research?

Pinealon research concentration typically ranges from 0.5mg/mL to 5mg/mL depending on administration route, animal model, and study duration. Subcutaneous protocols most commonly use 1–2mg/mL to allow practical injection volumes (50–200μL) while maintaining dose accuracy. Higher concentrations (3–5mg/mL) are reserved for intravenous or intramuscular routes where bioavailability is higher and volume limitations are stricter. The lyophilised peptide must be reconstituted in bacteriostatic water or sterile saline and stored at 2–8°C for no longer than 28 days post-reconstitution.

Yes, concentration matters. But not for the reason most researchers assume. The issue isn't peptide efficacy at lower concentrations; pinealon retains biological activity across a wide dilution range. The constraint is injection volume. Administering 500μL subcutaneously to a 25g mouse causes tissue trauma and variable absorption; the same dose delivered in 100μL at higher concentration produces consistent pharmacokinetics. This article covers how to calculate the optimal concentration for your study design, what reconstitution errors cause peptide degradation before you ever inject it, and why published protocols from Russian institutions use fundamentally different concentration ranges than Western labs.

Pinealon Pharmacokinetics and Bioavailability

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) originally developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series. The peptide acts on the pineal gland, specifically influencing melatonin synthesis and circadian rhythm regulation through poorly characterised receptor interactions. Unlike larger peptides, pinealon's low molecular weight (404.36 Da) allows it to cross cellular membranes more readily, but this same property makes it vulnerable to rapid renal clearance. The half-life in rodent models is approximately 2–4 hours depending on administration route.

Subcutaneous administration produces peak plasma concentration (Cmax) at 30–60 minutes with bioavailability ranging 40–65%, significantly lower than intravenous delivery (100% by definition). The concentration you prepare must account for this absorption differential. A 1mg dose delivered subcutaneously at 1mg/mL in 1mL volume will not produce the same systemic exposure as 1mg delivered intravenously at 5mg/mL in 0.2mL. The injection site depot effect and lymphatic drainage pathway fundamentally alter pharmacokinetics. Research published in the Bulletin of Experimental Biology and Medicine used 1mg/kg doses reconstituted to 1mg/mL for subcutaneous injection in rats, which translates to approximately 100μL injection volumes per 100g body weight.

Reconstitution Protocols and Stability Constraints

Lyophilised pinealon arrives as a white to off-white powder in sealed vials, typically supplied in 5mg or 10mg quantities. The reconstitution process is where most concentration errors occur. Not because researchers miscalculate, but because they don't account for peptide adherence to vial surfaces or incomplete powder dissolution. To reconstitute pinealon to 2mg/mL using a 5mg vial: add 2.5mL bacteriostatic water (0.9% benzyl alcohol) slowly down the vial wall, allow it to sit for 60 seconds without agitation, then gently swirl. Never shake. Until the solution is completely clear. Vigorous shaking introduces air bubbles that denature peptide bonds at the air-liquid interface.

Once reconstituted, pinealon must be stored at 2–8°C and used within 28 days. The bacteriostatic water prevents bacterial growth, but it does not prevent peptide degradation. Temperature excursions above 8°C accelerate hydrolysis of the Glu-Asp peptide bond, and repeated freeze-thaw cycles cause irreversible aggregation. We've observed researchers store reconstituted peptides at room temperature between injections. This reduces biological activity by an estimated 15–30% per week based on HPLC stability data from similar tripeptides. If your protocol requires concentrations below 0.5mg/mL, prepare the working dilution immediately before use rather than storing it long-term; lower concentration solutions degrade faster due to increased surface area-to-volume ratios.

Dose Calculation and Volume Constraints

The concentration you prepare must match both your target dose and your maximum practical injection volume. For subcutaneous administration in mice (20–30g body weight), injection volumes above 200μL per site cause tissue distension and unpredictable absorption kinetics. If your protocol calls for 1mg/kg dosing in a 25g mouse, that's a 0.025mg (25μg) dose. At 1mg/mL concentration, you'd inject 25μL, well within tolerance. But if you reconstitute to 0.25mg/mL, the same dose requires 100μL, and at 0.1mg/mL it requires 250μL, which is not feasible subcutaneously.

For rats (200–300g), the injection volume ceiling is approximately 500μL subcutaneously or 1mL intraperitoneally. A 1mg/kg dose in a 250g rat equals 0.25mg (250μg). At 1mg/mL this requires 250μL, acceptable subcutaneously; at 0.5mg/mL it requires 500μL, pushing the upper limit. Higher concentrations (2–5mg/mL) are advantageous when dosing schedules require multiple daily injections or when working with compounds where volume-to-dose ratio becomes prohibitive. Real Peptides supplies lyophilised peptides in standardised quantities that allow straightforward reconstitution to common research concentrations without requiring complex serial dilutions.

Comparison Table

Concentration	Typical Use Case	Injection Volume (1mg/kg in 25g mouse)	Stability Post-Reconstitution	Primary Advantage	Professional Assessment
0.5mg/mL	Long-term studies requiring daily dosing over 4+ weeks where small volume precision is less critical	50μL	28 days at 2–8°C	Minimises peptide waste in extended protocols	Acceptable for pilot studies but risks volume-related injection errors in smaller rodents
1mg/mL	Standard subcutaneous protocols in mice and rats; most published literature uses this range	25μL	28 days at 2–8°C	Balances practical injection volumes with dose accuracy	Recommended starting point for most preclinical work. Volume tolerance and concentration stability are both optimal
2mg/mL	Intraperitoneal or intramuscular administration where higher bioavailability compensates for smaller volumes	12.5μL	21 days at 2–8°C (higher concentration accelerates degradation slightly)	Reduces injection frequency in multi-dose studies	Preferred for IP protocols or when injection site reactions are a concern with larger volumes
5mg/mL	Intravenous bolus injection or continuous infusion studies requiring minimal fluid load	5μL	14–21 days at 2–8°C	Allows precise dosing in volume-restricted applications like IV tail vein injection	Use only when required by protocol constraints. Storage stability drops and peptide aggregation risk increases

What If: Pinealon Research Scenarios

What if I need to dose multiple animals daily from the same vial — will the peptide degrade faster with repeated access?

Yes, each time you pierce the vial septum with a needle, you introduce contamination risk and air exposure that accelerates degradation. Use an aseptic technique: swab the septum with 70% isopropyl alcohol before each draw, draw air into the syringe equal to your desired volume before inserting the needle (to prevent negative pressure), and never reinsert a used needle into the vial. For studies requiring 30+ doses from a single vial over several weeks, consider aliquoting the reconstituted solution into single-use sterile vials immediately after reconstitution. This eliminates repeated septum punctures and limits degradation to the individual aliquot you're using that day. Store unused aliquots at 2–8°C and track the 28-day stability window from the original reconstitution date, not from when you open each aliquot.

What if my protocol requires concentrations below 0.5mg/mL — can I dilute further without losing activity?

You can dilute pinealon below 0.5mg/mL, but stability drops significantly. At concentrations below 0.25mg/mL, peptide adherence to vial walls and tubing becomes a measurable source of dose loss. Up to 10–15% of the nominal concentration can be lost to surface binding in polypropylene containers. If your study design requires ultra-low concentrations, prepare the working dilution immediately before injection rather than storing it. Use siliconised glass vials or low-binding polypropylene tubes to minimise surface loss, and verify the actual delivered concentration with a Bradford protein assay or HPLC if dose precision is critical. For volume-limited applications where you need extremely low doses, it's better to use a more concentrated stock and deliver smaller volumes than to over-dilute and lose peptide to non-specific binding.

What if I accidentally left my reconstituted pinealon at room temperature overnight — is it still usable?

Probably not at full potency. Pinealon's Glu-Asp peptide bond is susceptible to hydrolysis at temperatures above 8°C, and an overnight room temperature exposure (8–12 hours at 20–25°C) likely reduced biological activity by 15–30%. You won't see visible changes. The solution will still appear clear. But receptor binding affinity decreases as the peptide structure degrades. If this was a one-time incident early in a study, document it and continue with the understanding that your effective dose may be lower than calculated. If it occurred late in a multi-week protocol where you've already collected baseline data, discard the vial and reconstitute fresh peptide rather than risk inconsistent dosing across timepoints. Temperature logging is standard practice in GLP-compliant labs for exactly this reason.

The Unvarnished Truth About Pinealon Research Concentrations

Here's the honest answer: most concentration recommendations in published pinealon studies don't explicitly state the volume constraints that drove the choice. Researchers report using '1mg/kg subcutaneously' without clarifying whether that was delivered in 50μL, 100μL, or 200μL. And that difference matters. If you replicate a published protocol concentration without knowing the injection volume used, you may inadvertently introduce a confounding variable that makes your results non-comparable. The Russian literature on Khavinson peptides frequently uses higher per-dose volumes than Western labs consider acceptable, which is why direct protocol translation sometimes produces unexpected variability.

The second unspoken issue: lyophilised peptide purity. Most suppliers list '≥95% purity' but don't specify whether that's by HPLC, mass spectrometry, or total peptide content including salts and excipients. A 5mg vial at 95% purity contains 4.75mg active peptide and 0.25mg of acetate salts, trifluoroacetic acid residue, or other synthesis byproducts. When you reconstitute that vial to '1mg/mL' by adding 5mL solvent, your actual pinealon concentration is 0.95mg/mL. For most research this difference is negligible, but if you're running dose-response curves or comparing results across batches, it compounds. We mean this sincerely: verify the actual peptide content with your supplier before assuming the vial label represents active compound mass.

Our experience working with peptide researchers shows that concentration optimisation is the single most overlooked variable in replication failures. Teams assume the peptide itself is the active variable and treat concentration as a solved problem. It's not. The concentration you use determines injection volume, which determines tissue trauma and lymphatic uptake, which determines bioavailability, which determines whether your study replicates published findings or produces inexplicably weak effects. Get the concentration right first, and the rest of the protocol falls into place.

Pinealon Concentration for Research: Final Insight

The concentration you prepare isn't just a practical constraint. It's a pharmacokinetic variable. A 1mg/kg dose delivered in 50μL has different absorption kinetics than the same dose in 200μL because depot formation, lymphatic drainage, and tissue distribution are all volume-dependent. If your results don't match published data, audit your injection volumes before assuming the peptide batch or animal strain is the issue. The concentration that works for a 300g rat doesn't translate linearly to a 25g mouse. The mechanism is identical; the math is not.

For researchers designing new protocols: start with 1mg/mL for subcutaneous administration unless specific constraints require otherwise. If you need precise dosing across a wide body weight range, prepare a concentrated stock (5mg/mL) and dilute individual doses immediately before injection. If stability is a concern because your study runs longer than four weeks, reconstitute in smaller batches rather than trying to extend the 28-day window. And if anyone tries to sell you 'stabilised' pinealon formulations claiming longer shelf life without refrigeration. Ignore them. The chemistry doesn't support it.

All compounds discussed on this page are sold for research use only and are not for human consumption.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Start by determining your target dose (typically 0.5–2mg/kg in rodent models) and maximum practical injection volume for your chosen route (200μL subcutaneous for mice, 500μL for rats). Divide the total dose by the volume to get your minimum concentration, then round up to the nearest standard concentration (0.5, 1, 2, or 5mg/mL). For example, a 1mg/kg dose in a 25g mouse equals 0.025mg — if you want to deliver this in 50μL, you need at least 0.5mg/mL concentration. If delivering in 25μL, you need 1mg/mL. Always confirm your final injection volume stays within physiological tolerance ranges for your animal model.

Yes, but storage duration drops significantly. Sterile 0.9% saline is appropriate for single-use reconstitution when you'll use the entire vial within 24 hours, but it lacks the bacteriostatic agent (typically 0.9% benzyl alcohol) that prevents microbial growth over longer storage. If using saline, prepare only the volume you need for that day's injections and discard any remainder. For multi-week protocols requiring repeated draws from the same vial, bacteriostatic water is non-negotiable — it extends usable shelf life from 24–48 hours to 28 days when stored at 2–8°C. Never use bacteriostatic water for neonatal animals or in protocols where benzyl alcohol could confound results.

Lyophilised pinealon stored at −20°C in sealed vials maintains stability for 24–36 months from the manufacture date, provided the vial has never been opened or exposed to moisture. The peptide is hygroscopic — atmospheric moisture exposure causes gradual degradation even in powder form. Once you break the vial seal to reconstitute, any unused powder should not be re-sealed and stored long-term. Most suppliers provide manufacturing and expiration dates on the label; use the expiration date as your stability guideline. If the powder appears discoloured (yellowing or browning) or clumped rather than fine and white, discard it regardless of the printed expiration date.

Subcutaneous and intraperitoneal routes tolerate larger volumes (200–500μL in mice, up to 1mL in rats), so concentrations between 0.5–2mg/mL work well. Intravenous injection requires much smaller volumes (typically 50–100μL for tail vein in mice) due to fluid load constraints, so concentrations of 3–5mg/mL are necessary to deliver therapeutic doses. Intramuscular injection sits between these extremes — volumes of 50–100μL are standard, requiring concentrations of 2–3mg/mL for most protocols. Bioavailability also varies: IV is 100%, IP is approximately 70–85%, subcutaneous is 40–65%, and IM is 60–75%. Your concentration choice must account for both volume limits and expected absorption efficiency.

Using excessively high concentrations (above 5mg/mL for pinealon) increases peptide aggregation risk and reduces storage stability without improving dosing accuracy. High-concentration solutions are more viscous, making injection technique more difficult and increasing the chance of partial-dose delivery or needle clogging. Additionally, higher concentrations accelerate hydrolysis of the peptide bonds during storage — a 10mg/mL solution might degrade 30–40% faster than a 1mg/mL solution stored under identical conditions. The only valid reason to use higher concentrations is when injection volume constraints make lower concentrations impossible, such as IV bolus protocols where fluid load must be minimised.

Yes, because peptide purity and salt content vary between manufacturers. A vial labelled '5mg pinealon' from one supplier might contain 4.8mg active peptide plus 0.2mg acetate salts, while another supplier's vial contains 4.5mg active peptide plus 0.5mg excipients and residual TFA. Both list '≥95% purity' but the actual concentration after reconstitution differs by up to 10%. For dose-critical studies or cross-batch comparisons, verify the actual peptide content with your supplier's certificate of analysis (COA), which should list HPLC purity and mass spectrometry confirmation. If the COA shows 92% purity instead of 98%, adjust your reconstitution volume accordingly to achieve your target working concentration.

Freezing reconstituted peptides is not recommended because freeze-thaw cycles cause peptide aggregation and irreversible loss of biological activity. When water freezes, ice crystal formation physically disrupts peptide structure, and the concentration gradient created during thawing promotes aggregation of hydrophobic residues. If you absolutely must store reconstituted pinealon longer than 28 days, aliquot it into single-use volumes immediately after reconstitution, freeze at −80°C (not −20°C), and thaw each aliquot only once. Expect 10–20% activity loss even with optimal freezing technique. For protocols requiring extended timelines, reconstitute smaller batches more frequently rather than relying on frozen storage.

Visible signs of degradation include cloudiness, precipitate formation, or colour change (yellowing). However, peptide degradation often occurs without visible changes — the solution remains clear but biological activity drops due to peptide bond hydrolysis. If you've stored reconstituted pinealon longer than 28 days, experienced any temperature excursions above 8°C, or subjected it to freeze-thaw cycles, assume reduced potency even if the solution looks normal. The only definitive way to confirm degradation is HPLC analysis comparing the peptide profile to a fresh standard. In practice, most researchers use storage time and temperature logs as surrogate markers — if your protocol spanned the full 28-day window, reconstitute fresh peptide for any follow-up experiments requiring exact dose replication.

Maintain the same concentration (mg/mL) but adjust the injection volume to match the new body weight-based dose. If you're using 1mg/kg in mice at 1mg/mL concentration (delivering 25μL to a 25g mouse), the same 1mg/kg dose in a 250g rat requires 250μL at 1mg/mL — the concentration stays constant, the volume scales with body weight. If the scaled volume exceeds your injection route's tolerance (e.g., 500μL is the subcutaneous ceiling for rats), increase the concentration proportionally: switching to 2mg/mL allows you to deliver the same dose in 125μL. Never change both concentration and dose simultaneously unless you're deliberately modifying the protocol — it introduces confounding variables that make cross-species comparisons unreliable.

In vitro pinealon concentrations typically range 1–100μM (approximately 0.0004–0.04mg/mL when accounting for molecular weight), far lower than in vivo concentrations because there's no absorption barrier or systemic clearance. Start with 10μM as a mid-range screening concentration and run dose-response curves (0.1μM, 1μM, 10μM, 100μM) to identify the optimal concentration for your specific cell line and endpoint. Reconstitute a high-concentration stock (1–5mg/mL) in sterile water or DMSO (for longer-term storage), then perform serial dilutions in cell culture medium immediately before treatment. DMSO vehicle concentration should never exceed 0.1% in the final culture medium to avoid solvent toxicity.

Concentration itself has minimal direct effect on tissue reactions — volume is the primary driver. A 200μL subcutaneous injection causes more tissue trauma and inflammation than a 50μL injection regardless of concentration, because the physical fluid bolus distends tissue and disrupts local blood flow. However, very high concentrations (above 10mg/mL) increase solution viscosity and osmolality, both of which can cause injection site pain and delayed absorption. For subcutaneous protocols, concentrations between 1–3mg/mL balance dose delivery with tissue tolerance. If you observe persistent injection site reactions (swelling lasting more than 2 hours, visible inflammation, self-trauma behaviour), reduce the injection volume first by increasing concentration moderately rather than diluting further and increasing volume.

Only if their molecular weights and solubility profiles are similar. Pinealon (404 Da) reconstitutes readily at concentrations up to 10mg/mL, but larger peptides or those with hydrophobic sequences may precipitate at concentrations above 2–3mg/mL. If running a multi-peptide study, calculate each peptide's concentration individually based on its dose requirement and volume constraint, then verify solubility with a test reconstitution before committing to bulk preparation. Using a single concentration across all peptides for convenience introduces dosing errors — what works for a 400 Da tripeptide won't necessarily work for a 3000 Da peptide with different pharmacokinetics.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA